.jpg)
.png)
NLA News
In 2014, the Foundation of the National Lipid Association (FNLA), Preventive Cardiovascular Nurses Association (PCNA), and Mended Hearts launched Cholesterol Counts, a program designed to accumulate Internet-based information on how much people know about their cholesterol, how much they care about... more
By Carl E. Orringer, MD, FACC; Pamela Bowe Morris, MD, FACC; Donald M. Lloyd-Jones, MD, FACC Guideline-directed patient care recommendations are based upon studies that make observations on groups of subjects who have specific characteristics and exhibit variable degrees of benefit or harm... more
WAYLIVRA, the only therapy available for Familial Chylomicronemia Syndrome (FCS), has been authorized as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis whose response to diet and triglyceride-lowering therapy has been inadequate, according to a... more
SCOTTSDALE, Ariz.—The National Lipid Association (NLA), a nonprofit, multidisciplinary medical society focused on enhancing the practice of lipid management in clinical medicine, marks a major milestone this year with its tenth anniversary. Lipid management involves the treatment of disruptions in... more
Regeneron Pharmaceuticals, Inc. today announced that the New England Journal of Medicine (NEJM) published positive results from the Phase 3 trial of evinacumab in 65 patients with homozygous familial hypercholesterolemia (HoFH). Evinacumab is an investigational medicine that... more
Arrowhead Pharmaceuticals is proud to announce the publication of two back-to-back NEJM manuscripts in the mixed hyperlipidemia population with plozasiran (MUIR study with APOC3 target) and zodasiran (ARCHES2 study with ANGPTL3 target) following the EAS presentations by Drs. Ballantyne and... more
The National Lipid Association (NLA) was in attendance at the recent American College of Cardiology (ACC) Annual Scientific Session and Expo 2015, March 14-16, in San Diego. The meeting was dedicated to the diagnosis, prevention and treatment of cardiovascular disease, taking an interactive and... more
FOURIER Trial Reveals Significant Reduction in Cardiovascular Risk Study results indicate that evolocumab significantly reduces the risk of cardiovascular events in patients with clinically evident ASCVD WASHINGTON, D.C., March 17, 2017 — The FOURIER trial lead investigators... more
Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the U.S. Food and Drug Administraion (FDA) has approved Praluent® (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established cardiovascular (CV)... more
Join NLA faculty as they present “Myopathy and More: Getting Statins to Work in the Real World” at the AHA Scientific Sessions in Los Angeles on Monday, November 5 from 7:30 to 8:45 a.m. Part of the session will focus on results from the USAGE survey, the largest known consumer... more